These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35920965)

  • 1. Management of Chronic Myeloid Leukemia in Children and Young Adults.
    Ford M; Mauro M; Aftandilian C; Sakamoto KM; Hijiya N
    Curr Hematol Malig Rep; 2022 Oct; 17(5):121-126. PubMed ID: 35920965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Myelogenous Leukemia in Childhood.
    Smith SM; Hijiya N; Sakamoto KM
    Curr Oncol Rep; 2021 Mar; 23(4):40. PubMed ID: 33718985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
    Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
    Expert Opin Drug Saf; 2024 Aug; 23(8):969-979. PubMed ID: 38873693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia].
    Slezáková K; Mistrík M; Bátorová A
    Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
    Nishiyama-Fujita Y; Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto K; Fujita H; Fujioka I; Tsuchiya S; Kimura Y; Iwanaga E; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
    Ann Med; 2022 Dec; 54(1):1244-1254. PubMed ID: 35486442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic myeloid leukemia: aiming for treatment free remission].
    Kimura S
    Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
    Jabbour E; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What is the best treatment for chronic-phase CML?].
    Sakaida E
    Rinsho Ketsueki; 2021; 62(8):1012-1023. PubMed ID: 34497187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Takaku T
    Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.
    Carofiglio F; Lopalco A; Lopedota A; Cutrignelli A; Nicolotti O; Denora N; Stefanachi A; Leonetti F
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.